Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25819734 | 0.86 | POLB (0.34) | OPRM1OPRD1OPRK1POLBSMN1; SMN2 | |
| SCHEMBL19237476 | 0.78 | CA12 (0.34) | KMT2AOPRM1OPRD1OPRK1SMN1; SMN2 | |
| SCHEMBL15281169 | 0.78 | MTNR1A (0.35) | LGALS3TSHR | |
| SCHEMBL25819728 | 0.78 | DPP4 (0.35) | POLBALDH1A1 | |
| SCHEMBL12377430 | 0.78 | SPR (0.37) | POLBTSHRALDH1A1LMNAKDM4E | |
| SCHEMBL18850696 | 0.77 | DPP4 (0.35) | — | |
| SCHEMBL22906473 | 0.77 | DPP4 (0.35) | — | |
| SCHEMBL18761189 | 0.75 | HDAC3 (0.35) | POLBSMN1; SMN2LGALS3 | |
| SCHEMBL19780569 | 0.74 | DPP4 (0.34) | ALDH1A1LMNA | |
| SCHEMBL15281105 | 0.73 | RAB9A (0.32) | SMN1; SMN2LGALS3ALDH1A1LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230220008-A1 | MULTIMERIC BICYCLIC PEPTIDE LIGANDS | BICYCLETX LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230220008-A1 | MULTIMERIC BICYCLIC PEPTIDE LIGANDS | CD40, TNFSF11, TNFRSF9 | KMT2A 4307/4885OPRM1 2236/4885OPRD1 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.